Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib with Gemcitabine and Cisplatin in Advanced Solid Tumors
NCT02537561Phase 1Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Dec 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of talazoparib in solid tumor and non-small cell lung cancer (NSCLC), sponsored by Washington University School of Medicine. Planned start Dec 2015; status: withdrawn.
02
Drugs
talazoparib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02537561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02537561.